By Sebastian Gensior — 02 Aug 2026

The Weekly Term Sheet (2026-W31)

M&A was led by argenx / Forte (about $2.2B all-cash for the anti-CD122 antibody FB102) and Johnson & Johnson's build-to-buy on Flagship's Sail Biomedicines ($785M up front plus a $2.58B buyout option), neither carrying a running royalty. Two reverse mergers (Synlogic / Caldera, Processa / Vidya) and one SPAC (Oak Hill Bio / RA Capital) listed private assets, and American Industrial Partners closed its $1.272B Avanos take-private.

Royalty origination ran to nine licence-outs, mostly on China, Japan, or private originators. IMPACT / Pharmanovia leads the disclosed rates at a tiered mid-20s% on senaparib. The sharpest royalty read is an unlicensed one: AstraZeneca's sonesitatug vedotin hit Phase 3 gastric overall survival while carrying a tiered royalty back to Keymed and its KYM Biosciences vehicle.

Funding stayed modest: one IPO priced (Apnimed, $192M), one on file (Vogenx), two grants, and four rounds and secondaries. Three blue-chips reported (AstraZeneca, GSK, Sanofi). The week's sharpest single move was legal: the Federal Circuit extinguished the University of Texas's royalty on Boston Scientific's drug-eluting stents.

Highlights:

Royalty events: 3, all restructurings, none a purchase. Gossamer / Chiesi (seralutinib rights back, inbound ex-US royalty flipped to a capped payable, 27 Jul); Xencor / Alexion ($105M settles the US Ultomiris leg, ex-US continues, 29 Jul); PetVivo / VetStem (vet PrecisePRP licence terminated, 28 Jul).
M&A and strategic: 2 large, 2 recaps, 1 completion. argenx / Forte (~$2.2B all-cash, FB102, 27 Jul); J&J / Sail (in vivo CAR-T; $785M up front plus a $2.58B buyout option, no running royalty, 29 Jul); reverse mergers Synlogic / Caldera and Processa / Vidya (29 Jul); AIP / Avanos ($1.272B, closed, 27 Jul).
Reverse merger: Oak Hill Bio / RA Capital SPAC. ~$175M to list the Phase 3 Angelman ASO rugonersen; upstream Roche royalty; 27 Jul.
Licence-outs and collaborations: 9, mostly China, Japan, or private originators. IMPACT / Pharmanovia leads on rate (senaparib, tiered mid-20s%, 31 Jul), then Taisho / Kaigene, AB2 Bio / Nippon Shinyaku, AbCellera / Vertex, Relation / GSK, Idorsia / Jamjoom, Freenome / Abbott ($100M milestone), Sinopharm / Harbour, Eisai / CORE.
Royalty-bearing re-rate: AstraZeneca / sonesitatug vedotin. Phase 3 gastric OS win, a first for an anti-CLDN18.2 ADC; tiered royalty to Keymed / KYM; 27 Jul.
Clinical and regulatory re-rates: 11 (9 positive, 2 negative). Positive royalty reads: GSK / Hansoh ris-rez, Corbus / CRB-701 (CSPC), Atea / BEM-RZR (Merck). Also positive: InnoCare, MapLight, Altimmune, Pfizer / LITFULO, and Replimune / RP1 (adcomm 10-3 on 30 Jul, reversing a 28 Jul setback; PDUFA 2 Aug). Negative: AstraZeneca / Ultomiris and Karyopharm / selinexor (endometrial miss caps its ex-US royalty base).
Legal / IP: 2. Federal Circuit extinguished the University of Texas royalty on Boston Scientific stents (27 Jul); Roche / Genentech sued Biocon over a Perjeta biosimilar (base defence, no stream).
Regulatory review: 1. J&J / RYBREVANT FASPRO, FDA Priority Review in head and neck cancer; widens the Genmab (8-10%) and Halozyme royalty base; 30 Jul.
Platform collaborations: 2, no stream. J&J / Sail (scored under M&A); ICON / Anthropic (Claude across ICON's Orbis trial platform; 28 Jul).
Funding: 1 IPO priced, 1 on file, 2 grants, 4 rounds/secondaries. Apnimed priced ($192M, APMD, 30 Jul); Vogenx on file (Kissei royalty); Claris ($118M, Kringle royalty); CORE ($21M, above an Eisai royalty); Lauxera / GenePlanet; Xeltis (€20.5M); Micron / NIAID ($4.5M).
Milestone: Keros / Takeda. $20M on Phase 3 ELRiSE MDS first dosing (elritercept); 30 Jul.
Earnings: 3. AstraZeneca H1, GSK Q2, Sanofi Q2; Sanofi's €1,031M impairment and Alnylam's same-day guidance cut are the sharper royalty reads.
Standing passes. Veterinary: only PetVivo / VetStem. Fund formation: no new close.
W30 gap-catches (logged, not restated): Otsuka / SIMTRIYO, Outlook / LYTENAVA, Almirall / Certest, DualityBio / BioNTech DB-1311.
Watch into W32: Replimune RP1 PDUFA (2 Aug); argenx / Forte tender close (Q3).

Royalty Monetisations and Restructuring

Gossamer Bio / Chiesi: Worldwide Seralutinib Rights Reacquired at No Upfront Cash, Flipping an Inbound Ex-US Royalty Into a Capped Payable to the Former Partner (Mon July 27)

Gossamer Bio (Nasdaq: GOSS) announced that it has reacquired worldwide development and commercial rights to seralutinib from Chiesi Farmaceutici, terminating the May 2024 global collaboration, alongside a Pre-NDA regulatory update and approved capital-structure changes (Gossamer release).

Reacquirer / owner: Gossamer Bio, Inc. (Nasdaq: GOSS; San Diego; clinical-stage, seralutinib for PAH and PH-ILD)
Counterparty: Chiesi Farmaceutici S.p.A. (Parma, Italy; former ex-US licensee and US 50/50 partner)
Asset: seralutinib, inhaled PDGFRalpha/beta, CSF1R, and c-KIT inhibitor via dry powder inhaler; pulmonary arterial hypertension (PAH) and PH-ILD
Prior structure (May 2024, terminated): Chiesi exclusive ex-US rights; escalating mid-to-high-teens royalty to Gossamer on ex-US net sales; US 50/50 profit share; $160M development reimbursement; up to $146M regulatory and $180M sales milestones
New structure: Gossamer reacquires worldwide rights at no upfront cash; Chiesi pays Gossamer a one-time $5M settling all prior obligations including Q2 2026 costs; Chiesi entitled to a capped royalty on worldwide net sales (no obligation once the cap is reached) plus specified milestone payments
Royalty: Inbound ex-US mid-to-high-teens royalty to Gossamer extinguished; replaced by a capped worldwide royalty payable to Chiesi. Net effect: a finite, self-extinguishing payable in exchange for consolidated global economics
Regulatory: Pre-NDA Type B meeting (mid-June) plus minutes; PAH NDA targeted September 2026; FDA framed PROSERA statistical and effect-size questions as review, not filing, issues; filing on one adequate and well-controlled study (PROSERA) plus confirmatory evidence (Phase 2 TORREY, May 2026 CT imaging substudy); potential approval decision Q3 2027
Capital structure: Convertible note exchange and reverse stock split approved; cash about $57M at June 30, 2026
Advisers: None disclosed in the announcement
Context: The closest approved mechanistic parallel is Merck's Winrevair (sotatercept, March 2024), which targets pulmonary vascular remodelling as a biologic rather than an inhaled small molecule.
Date: Announced Mon July 27, 2026

Xencor / Alexion: A Disputed Ultomiris US Royalty Settled for a $105M Lump Sum, a Forced Monetisation With an OMERS Overlay (Wed July 29)

Xencor (Nasdaq: XNCR) agreed to receive $105M from Alexion Pharma International Operations (the AstraZeneca rare-disease unit) to resolve a commercial dispute over US royalties on Ultomiris (ravulizumab-cwvz), the XmAb Fc-engineered complement inhibitor Xencor licensed to Alexion (Xencor release).

Licensor / royalty holder: Xencor, Inc. (Nasdaq: XNCR; Pasadena; XmAb Fc engineering)
Licensee / payer: Alexion Pharma International Operations Limited (Ireland; AstraZeneca / Alexion)
Asset: Ultomiris (ravulizumab-cwvz), long-acting C5 complement inhibitor; the royalty derives from Xencor's XmAb Fc half-life technology under the January 28, 2013 Option and License Agreement (as amended)
Structure: Settlement of a US-royalty dispute (Alexion's non-payment position surfaced March 2, disclosed March 4, 2026); Xencor receives $105M in two equal $52.5M payments (first August 2026, second within 14 days of the one-year anniversary); Alexion's US royalty obligation extinguished; ex-US royalties continue under the same licence
Royalty: A disputed low-single-digit US royalty (Xencor had guided to $100M to $120M remaining through 2028 in Dec 2025) converted to a fixed $105M lump sum, crystallising close to full expected value; ex-US leg intact; prior OMERS Life Sciences purchase (November 2023, $215M for portions of the Ultomiris and Monjuvi royalties and milestones) sits over the same underlying stream
Context: A reminder that a licensee's unilateral decision to stop paying can reach through to a downstream royalty owner: dispute risk is live even on a marketed, blue-chip-partnered stream sitting under an aggregator (OMERS) purchase.
Date: Announced Wed July 29, 2026 (8-K Item 1.01)

PetVivo / VetStem: A Veterinary PrecisePRP Licence Terminated, Unwinding a Net-Sales Royalty to the Originator (Tue July 28)

PetVivo Holdings (OTCQX: PETV) and VetStem, Inc. entered a Termination and Settlement Agreement, effective July 24, 2026, that ends their Exclusive License and Supply Agreement for the PrecisePRP (platelet-rich plasma) product line for horses and companion animals (PetVivo release / 8-K).

Parties: PetVivo Holdings (OTCQX: PETV; licensee) and VetStem, Inc. (licensor, patent owner)
Product: PrecisePRP Canine and Equine (platelet-rich plasma) for horses and companion animals
Structure: Termination and Settlement Agreement effective July 24, 2026 (announced July 28); rights and inventory revert to VetStem; accrued royalties, milestones, and invoices extinguished; PetVivo pays $75,000 total plus a possible inventory top-up; VetStem's 250,000-share warrant unchanged
Royalty: PetVivo's net-sales royalty to VetStem (rate undisclosed; original February 13, 2025 licence, term to the later of ten years from first sale or last patent claim) terminated
Context: A small OTC example, but a clean one of a veterinary net-sales royalty dissolved rather than monetised.
Date: Announced Tue July 28, 2026 (agreement effective July 24; 8-K Item 1.02)

M&A and Restructuring

argenx (Euronext and Nasdaq: ARGX) agreed to acquire Forte Biosciences (Nasdaq: FBRX) for $77 per share in cash, a total equity value of about $2.2B, adding the first-in-class anti-CD122 antibody FB102 to its immunology pipeline (argenx release).

Acquirer: argenx SE (Euronext and Nasdaq: ARGX; CEO Karen Massey)
Target: Forte Biosciences, Inc. (Nasdaq: FBRX; Dallas, Texas; CEO and Chairperson Paul A. Wagner, Ph.D.)
Structure: All-cash tender offer via a wholly owned subsidiary at $77 per share; total equity value about $2.2B; premium about 86% to VWAP since July 9, 2026 positive vitiligo data and about 41% over the July 24 close; subject to majority tender and antitrust clearance; expected close Q3 2026
Asset: FB102, first-in-class anti-CD122 monoclonal antibody targeting pathogenic T-cell and NK-cell activity while preserving regulatory T cells; vitiligo, celiac disease, alopecia areata, and other autoimmune indications; FDA Fast Track in celiac disease; Phase 1b proof-of-concept in vitiligo and celiac; Phase 2 celiac readout expected year-end 2026
Background: argenx participated in Forte's about $150M April 2026 public offering; the two Phase 1b readouts drove the move from investment to acquisition
Royalty: None disclosed as travelling; FB102 described as proprietary;
Advisers: Goldman Sachs International as financial adviser to argenx (named in the release); Forte's advisers to be confirmed from the SC 14D-9
Context: The $77 price is about 86% over Forte's VWAP since its July 9 vitiligo readout (about 41% over the July 24 close); argenx had already seeded the position via Forte's roughly $150M April 2026 offering, and frames FB102 as complementing efgartigimod (Vyvgart / Vyvgart Hytrulo).
Date: Announced Mon July 27, 2026

Oak Hill Bio / Research Alliance Corp III: SPAC Business Combination Takes a Phase 3 Angelman ASO Public, on Rights Licensed From Roche (Mon July 27)

Oak Hill Bio (OHB Pediatrics Ltd.) agreed to a business combination with Research Alliance Corporation III (Nasdaq: RACC), a SPAC sponsored by RA Capital Management, to create a Nasdaq-listed rare-disease company advancing rugonersen, an antisense oligonucleotide for Angelman syndrome (Oak Hill / RACC release).

Target / operating company: Oak Hill Bio (OHB Pediatrics Ltd.; Cambridge, MA; CEO Josh Distler)
Acquirer / listing vehicle: Research Alliance Corporation III (Nasdaq: RACC), SPAC sponsored by RA Capital Management; to be renamed Oak Hill Bio, Inc. (Nasdaq: OAKH)
Asset: rugonersen (RO7248824 / OHB-724), antisense oligonucleotide derepressing paternal UBE3A; Angelman syndrome; Phase 3 BEACON (first patient dosed July 2026)
Structure: Business combination providing about $175M gross ($75M RACC trust, backstopped by RA Capital, plus $100M committed private financing); funds rugonersen through Phase 3 readout and potential NDA in 2H2029; close expected year-end 2026
Royalty: Rugonersen exclusively licensed from Roche (February 2025, global rights); an upstream Roche royalty and milestone stack rides on the asset; rate and schedule not disclosed in any public filing
Advisers: Leerink Partners, UBS Investment Bank, Wells Fargo Securities, and LifeSci Capital as joint PIPE placement agents; Leerink Partners also exclusive financial adviser to RACC; Goodwin Procter (Oak Hill Bio), Cooley (RACC), and Kirkland & Ellis (placement agents) as legal counsel; former Avidity CFO Mike MacLean to remain on the combined board
Context: Oak Hill's model is to acquire deprioritised late-stage assets on attractive licence terms, so each program tends to carry an upstream originator royalty; rugonersen came from Roche despite encouraging TANGELO data, and a June 2026 $32.5M Series A stacks with the $175M here.
Date: Announced Mon July 27, 2026

American Industrial Partners / Avanos Medical: $1.272B Take-Private Closes (Completion, Mon July 27)

Completion of a previously announced print, logged for the record. American Industrial Partners closed its acquisition of Avanos Medical (formerly NYSE: AVNS) on July 27, 2026, a take-private valued at about $1.272B, $25.00 per share in cash, a 72.1% premium to the April 13 undisturbed close, first announced April 14, 2026, with the stockholder vote covered in W30. Avanos, a medtech maker of specialty-nutrition and enteral-feeding and pain-management and opioid-reduction products (2025 net sales $701.2M), delists from the NYSE and becomes private. No pharmaceutical royalty travels. J.P. Morgan advised Avanos, with Alston & Bird as legal counsel. A large medtech completion reaching close in-window.

Johnson & Johnson / Sail Biomedicines: A Build-to-Buy on In Vivo CAR-T, $785M Up Front Plus a $2.58B Acquisition Option, Structured on Milestones Rather Than a Running Royalty (Wed July 29)

Johnson & Johnson (NYSE: JNJ), through Janssen Biotech, announced strategic agreements and a collaboration with Sail Biomedicines, the Flagship Pioneering company building in vivo CAR-T therapies for immune-mediated disease, together with an equity investment and an exclusive option to acquire Sail outright (J&J release; Sail release).

Acquirer / partner: Johnson & Johnson (NYSE: JNJ), via Janssen Biotech (collaboration) and JJDC (equity)
Target / partner: Sail Biomedicines (private; Cambridge, MA; a Flagship Pioneering company; Executive Chairman John Mendlein)
Structure: Strategic collaboration plus equity plus an exclusive option to acquire; total initial payments $785M (incl. $465M equity), up to $140M development milestones (about $925M initially); exclusive option to acquire Sail for a further $2.58B; option exercise expected to dilute adjusted EPS by about $0.18 (2026) and $1.28 (2027)
Asset / platform: In vivo CAR-T for immune-mediated / autoimmune disease; lead SAIL-0839 (preclinical); eRNA (endless RNA) plus programmable targeted-nanoparticle platform (Senda + Laronde heritage); four preclinical programs
Royalty: None disclosed; economics run through the upfront, equity, milestone ladder, and fixed option price; full ownership on exercise; any Flagship-Sail upstream not public
Advisers: Leerink Partners (J&J side); others not disclosed
Context: It slots into the in vivo CAR-T land grab that has drawn AbbVie, AstraZeneca, BMS, Gilead / Kite, and Lilly (which paid $3.25B up front for Kelonia in April 2026); analysts read the dilution guidance as signalling a near-term buyout.
Date: Announced Wed July 29, 2026

Synlogic / Caldera Therapeutics: A Newco Combination and $278M PIPE to List an IBD Bispecific That Carries a China (Qyuns) Royalty (Wed July 29)

Synlogic (OTC: SYBX) and privately held Caldera Therapeutics agreed to combine in an all-stock transaction under which both companies become wholly-owned subsidiaries of a newly formed holding company that will operate as Caldera Therapeutics and develop CLD-423, a TL1A x IL-23p19 bispecific antibody for inflammatory bowel disease, alongside a concurrent upsized $278M private placement (Synlogic / Caldera release).

Parties: Synlogic (OTC: SYBX) and privately held Caldera Therapeutics both become wholly-owned subsidiaries of a newly formed holding company operating as Caldera Therapeutics (intends to list on the Nasdaq Capital Market as CALD); Caldera's board and CEO Praveen Tipirneni lead the combined company
Structure: All-stock combination via a newly formed holding company (a double-holdco, not a Synlogic-shell reverse merger) plus a concurrent upsized $278M private placement; pro forma ownership pre-merger Caldera about 62.8%, private-placement investors about 34.9%, Synlogic holders about 2.3% (Synlogic stake subject to net-cash adjustment; implied valuations Synlogic $18M assuming $6M net cash, Caldera $500M); runway into 2029; close expected early 2027
Asset: CLD-423, TL1A x IL-23p19 bispecific for IBD (ulcerative colitis, Crohn's) and other immune-mediated disease; Phase 1 complete, Phase 2 next
Royalty: Upstream Qyuns Therapeutics (China) licence on CLD-423; milestone and royalty schedule undisclosed; a China-origin royalty riding to a US listing
PIPE syndicate: Bain Capital Life Sciences, TCGX, Atlas Venture, venBio Partners, Omega Funds, Blackstone Multi-Asset Investing, LAV, Wellington Management, Janus Henderson Investors, Sirenia Capital Management, Vivo Capital, and further mutual funds and institutional investors
Advisers: Lucid Capital Markets (Synlogic financial adviser); Mintz (Synlogic legal counsel); Jefferies, TD Cowen, Guggenheim, UBS, LifeSci Capital (placement agents); Fenwick (Caldera), Cooley (agents)
Context: Another China-originated royalty (Qyuns) reaching the US public market through a shell.
Date: Announced Wed July 29, 2026

Processa / Vidya Therapeutics: A Stock-for-Stock Acquisition and ~$200M PIPE to Recapitalise Around a CNS-Penetrant BTK Inhibitor (Wed July 29)

Processa Pharmaceuticals (Nasdaq: PCSA) acquired Vidya Therapeutics in a stock-for-stock deal, adding the CNS-penetrant covalent BTK inhibitor VT-7208, alongside an oversubscribed private placement of about $200M (Processa release).

Acquirer / target: Processa Pharmaceuticals (Nasdaq: PCSA) acquires Vidya Therapeutics (private; lead VT-7208)
Structure: Stock-for-stock acquisition plus an oversubscribed ~$200M private placement (Series A convertible preferred); fully diluted ownership about 0.9% legacy Processa / 46% Vidya / 52.6% PIPE; runway into 2H 2029
Asset: VT-7208, CNS-penetrant once-daily oral covalent BTK inhibitor; Phase 2 planned in food allergy, CSU, and RMS
Royalty: None disclosed; VT-7208 is Vidya's own asset
Advisers: Leerink (Vidya adviser and PIPE lead agent); Evercore, UBS, Wells Fargo (co-agents); Tungsten Advisors (Processa, fairness opinion); Cooley (Vidya), Katten (Processa), Mintz (agents)
Context: Like Synlogic / Caldera, a recapitalisation more than a royalty story: legacy holders about 0.9%, Vidya about 46%, PIPE about 52.6%, with Bain, Janus Henderson, RA Capital, ADAR1, Cormorant, and Soleus in the syndicate.
Date: Announced Wed July 29, 2026

Royalty-Bearing License-Outs and Collaborations

Pfizer / Eisai: Japan Co-Promotion of Nurtec (Rimegepant) From September 1, Widening the Net-Sales Base on a Legacy-Royalty CGRP Asset (Mon July 27)

Pfizer Japan and Eisai (TSE: 4523) agreed to co-promote Nurtec OD Tablet 75mg (rimegepant sulfate hydrate), the oral CGRP receptor antagonist for the acute treatment and prophylaxis of migraine, in Japan from September 1, 2026 (Pfizer / Eisai release).

Partners: Pfizer Japan Inc. (commercial lead; development, manufacturing, distribution, commercialisation) and Eisai Co., Ltd. (TSE: 4523; co-promotion, appropriate-use information)
Product: Nurtec OD Tablet 75mg (rimegepant sulfate hydrate), oral CGRP receptor antagonist; acute treatment and prophylaxis of migraine
Structure: Co-promotion in Japan from September 1, 2026; no rights transfer, no new stream created
Royalty read-through: Rimegepant carries legacy upstream economics from the original Biohaven in-licence (acquired by Pfizer in 2022); the co-promotion widens the Japanese net-sales base on which that entitlement runs; specific legacy terms to be sourced
Context: Rimegepant reached Pfizer via the 2022 Biohaven acquisition; the co-promotion widens the base in a market where migraine affects an estimated 8.4% of adults.
Date: Announced Mon July 27, 2026

Idorsia / Jamjoom Pharma: Saudi and Levant Commercialisation Licence for QUVIVIQ (Daridorexant), Idorsia Taking Upfront Plus Royalties (Mon July 27)

Idorsia (SIX: IDIA) granted Jamjoom Pharmaceuticals exclusive distribution and commercialisation rights to QUVIVIQ (daridorexant), its dual orexin receptor antagonist for insomnia, in Saudi Arabia and the Levant (Idorsia release).

Licensor: Idorsia Ltd (SIX: IDIA; Allschwil, Switzerland)
Licensee: Jamjoom Pharmaceuticals Factory Co. (Saudi Arabia)
Product: QUVIVIQ (daridorexant), dual orexin receptor antagonist; insomnia
Territory: Saudi Arabia and the Levant (exclusive); Jamjoom holds the marketing authorisation
Royalty: Idorsia receives upfront plus royalties on net sales; Idorsia owns the asset (ex-Actelion), so no upstream burden; terms undisclosed
Context: Extends a QUVIVIQ partnering pattern that already spans Mochida (Japan), Latin America, and other Asia-Pacific and Middle East arrangements; daridorexant is ex-Actelion, so Idorsia carries no upstream burden.
Date: Announced Mon July 27, 2026

Freenome / Abbott: SimpleScreen CRC FDA Approval Triggers a $100M Milestone to Freenome Under the 2025 US Commercialisation Deal (Mon July 27)

The FDA approved Freenome's (Nasdaq: FRNM) SimpleScreen CRC blood-based colorectal-cancer screening test for average-risk adults 45 and older, and Abbott (NYSE: ABT) will exclusively commercialise it in the US from autumn 2026 (Freenome / Abbott release).

Originator: Freenome, Inc. (Nasdaq: FRNM; blood-based early cancer detection)
Commercial partner: Abbott (NYSE: ABT; exclusive US commercialisation, launch autumn 2026)
Product: SimpleScreen CRC, blood-based colorectal-cancer screening; adults 45+ at average risk; PREEMPT CRC validation (48,000+ enrolled; 81.1% CRC sensitivity, 90.4% specificity)
Economics: $100M milestone from Abbott to Freenome on FDA approval, under the August 2025 commercial agreement; ongoing revenue-share or royalty terms undisclosed
Date: Announced Mon July 27, 2026

Sinopharm / Harbour BioMed: Platform R&D Consortium on the Harbour Mice Antibody Engine, Terms Undisclosed (Mon July 27)

Harbour BioMed (HKEX: 02142) and Sinopharm (China National Pharmaceutical Group) formed the Sinopharm-Harbour BioMed Innovation Consortium to co-develop innovative biologics in oncology and immune-mediated inflammatory disease (Harbour release).

Platform owner: Harbour BioMed (HKEX: 02142; Harbour Mice fully human antibody platform)
Partner: Sinopharm (China National Pharmaceutical Group)
Structure: Sinopharm-Harbour BioMed Innovation Consortium; joint R&D funding, shared product rights; oncology and immune-mediated inflammatory disease
Royalty: Undisclosed; platform milestone and royalty entitlements typical but not disclosed; no stream stated
Context: Extends Harbour's platform partnerships, which already include AstraZeneca, BMS, and Pfizer.
Date: Announced Mon July 27, 2026

Eisai / CORE Biomedicine: Eisai Out-Licenses Multiple Preclinical Oncology Programs to a Newco, Retaining Milestone and Royalty Economics (Tue July 28)

Eisai (TSE: 4523) granted CORE Biomedicine exclusive global rights to develop and commercialise multiple preclinical oncology programs originally discovered by Eisai and its affiliates (CORE release).

Licensor: Eisai Co., Ltd. (TSE: 4523; originator of the programs)
Licensee: CORE Biomedicine (private; precision oncology; US, Japan, China)
Assets: Multiple preclinical oncology programs across distinct targets and pathways; exclusive global development and commercialisation rights to CORE
Royalty: Eisai retains milestone and royalty economics as licensor; terms undisclosed
Context: Eisai monetising shelved or non-core preclinical assets through a purpose-built newco rather than developing them in-house.
Date: Announced Tue July 28, 2026

Taisho Pharmaceutical / Kaigene: Exclusive Japan Licence to the FcRn Inhibitor KG006, a Royalty-Bearing Regional Out-Licence Stacked on a US Originator (Thu July 30)

Kaigene, Inc. (private; Rockville, MD) granted Taisho Pharmaceutical exclusive rights to develop, register, and commercialise KG006, its next-generation anti-FcRn antibody for autoantibody-mediated autoimmune disease, in Japan (Kaigene release).

Licensor / originator: Kaigene, Inc. (private; Rockville, MD; PDEG platform; CEO Minjae Shin)
Licensee: Taisho Pharmaceutical (Japan; exclusive Japan rights to develop, register, commercialise)
Asset: KG006 (Celltrion designation CT-P77), next-generation anti-FcRn antibody; autoantibody-mediated autoimmune disease; subcutaneous, patient-administered
Economics: $5M upfront; up to a combined $22M plus ¥57.5B (about $351M) in development, regulatory, and sales milestones; tiered royalties on Japan net sales; three-way MRCT with Celltrion
Royalty stack: Kaigene retains tiered royalties from Taisho (Japan) layered on the November 2025 Celltrion licence (ex-Greater-China-ex-Japan; $8M up, up to $736M milestones, tiered royalties); Kaigene keeps Greater China; a two-licensee royalty position on a single PDEG-platform asset
Context: The FcRn class is validated and crowded (argenx Vyvgart Hytrulo, UCB Rystiggo, J&J Imaavy), so KG006's deep pathogenic-antibody degradation and patient-administered dosing are the differentiators; Taisho brings Nanozora commercialisation experience.
Date: Announced Thu July 30, 2026

AB2 Bio / Nippon Shinyaku: A Japan Partner Exercises Its US Option on Tadekinig Alfa, Crystallising a Private Swiss Originator's Royalty Ladder (Thu July 30)

AB2 Bio (private; Lausanne, Switzerland) announced that Nippon Shinyaku (Japan) exercised its exclusive option to commercialise Tadekinig alfa (recombinant human IL-18 binding protein) in the United States, under the companies' 2025 option-and-licence agreement (AB2 Bio release).

Licensor / originator: AB2 Bio Ltd (private; Lausanne, Switzerland)
Licensee: Nippon Shinyaku Co., Ltd. (Japan; exclusive US commercialisation)
Asset: Tadekinig alfa (recombinant human IL-18 binding protein); primary monogenic IL-18-driven hyperinflammatory syndrome (NLRC4, XIAP); FDA Breakthrough Therapy designation
Economics: $30M option-exercise payment on exercise (plus a $6M option fee taken in 2025); eligible for up to $100M development milestones and up to $500M commercial-milestone-and-royalty payments; AB2 Bio retains all other indications worldwide and all ex-US rights in the lead indication and leads US BLA prep
Royalty: Originator milestone-and-royalty ladder to AB2 Bio on US net sales via the Japan licensee; a private-company, rare-disease royalty
Context: A privately held Swiss biotech converting an option into a milestone-and-royalty ladder on a first-in-class rare-disease biologic, with US economics flowing back from a Japanese licensee, the private-originator profile CFC tracks most closely.
Date: Announced Thu July 30, 2026

Relation Therapeutics / GSK: An Expanded AI Discovery Pact Adds Up to $110M on Top of a Milestone-and-Royalty-Bearing 2024 Base (Thu July 30)

Relation Therapeutics (private; UK) expanded its drug-discovery collaboration with GSK, adding up to $110M in upfront and success-based milestone payments to generate large-scale human cellular-perturbation datasets and feed them into models including Relation's MORGAN foundation model (Latham & Watkins notice, 31 Jul).

Parties: Relation Therapeutics (private; UK; CEO David Roblin) and GSK
Structure: Expansion of the December 2024 collaboration; up to $110M in upfront and success-based milestones for large-scale human cellular-perturbation data and model deployment (MORGAN foundation model); base deal ($45M incl. $15M equity, plus about $63M reachable) carries milestones and royalties
Royalty: Contingent originator royalties to Relation under the base agreement on any resulting programs; product-level rate not disclosed
Advisers: Latham & Watkins advised GSK (London corporate partner Lydia Torne, associate Luke Nauth)
Context: The royalty leg sits in the December 2024 base collaboration (fibrosis and osteoarthritis; $45M including $15M equity, about $63M reachable); the July expansion enlarges the data scope and milestone pool.
Date: Announced Thu July 30, 2026

AbCellera / Vertex: A TCE Platform Deal, $28M Up Front Plus Milestones and Tiered Royalties to the Originator (Wed July 29)

AbCellera (Nasdaq: ABCL) entered a collaboration with Vertex Pharmaceuticals (Nasdaq: VRTX) to discover, develop, manufacture, and commercialise multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions (AbCellera release).

Originator / platform: AbCellera Biologics (Nasdaq: ABCL; Vancouver; TCE platform)
Partner: Vertex Pharmaceuticals (Nasdaq: VRTX; funds all R&D, holds development and commercial rights)
Structure: $28M total upfront to AbCellera; preclinical, development, regulatory, and commercial milestones plus tiered royalties on net sales; optional AbCellera cell-line, process-development, and Phase-1 manufacturing; autoimmune and other conditions
Royalty: Tiered originator royalty to AbCellera on net sales, plus a milestone ladder; rate undisclosed
Context: The TCE platform's second pharma client of the summer, after a Jazz Pharmaceuticals deal a month earlier (about $56M upfront and up to roughly $792M to $820M per program).
Date: Announced Wed July 29, 2026 (AbCellera 8-K)

IMPACT Therapeutics / Pharmanovia: Senaparib Out-Licensed Across 66 Countries at up to €423.5M, the Week's Highest Disclosed Royalty Band (Fri July 31)

IMPACT Therapeutics (HKEX: 07630) granted Pharmanovia exclusive rights to manufacture, develop, and commercialise its PARP inhibitor senaparib (IMP4297) across Europe, the Middle East and North Africa, Australia, and New Zealand, for maintenance monotherapy in advanced high-grade ovarian, fallopian-tube, and primary-peritoneal cancer (IMPACT release).

Licensor / originator: IMPACT Therapeutics (HKEX: 07630; Shanghai; retains rights outside the licensed territories)
Licensee: Pharmanovia (global specialty pharma; 66 countries across EU, UK, EEA, Switzerland, MENA, Australia, New Zealand)
Asset: senaparib (IMP4297), internally discovered oral PARP inhibitor; maintenance monotherapy in advanced ovarian, fallopian-tube, and primary-peritoneal cancer; EMA MAA (1L ovarian maintenance) accepted Aug 2025, approval expected 2H 2026
Economics: up to €423.5M total (upfront plus near-term regulatory and commercial-milestone payments) plus tiered royalties rising into the mid-twenties percent of net sales (the week's highest disclosed band)
Royalty: Tiered originator royalty to IMPACT reaching the mid-20s% on ex-China licensed-territory net sales
Context: The mid-20s% band is the week's steepest disclosed royalty; senaparib is IMPACT's own oral PARP inhibitor, already launched and reimbursed in China, with an EMA MAA for first-line ovarian maintenance accepted August 2025 and approval expected 2H 2026.
Date: Announced Fri July 31, 2026 (HKEX voluntary announcement 30 Jul; PR 31 Jul)

ICON / Anthropic: A Multi-Year AI Collaboration Across the Clinical-Trial Lifecycle, Logged for Scope With No Stream (Tue July 28)

ICON plc (Nasdaq: ICLR), one of the largest clinical research organisations, announced a multi-year collaboration with Anthropic to embed Claude's capabilities across its Orbis agentic-AI platform (ICON release).

Parties: ICON plc (Nasdaq: ICLR; Dublin) and Anthropic
Structure: Multi-year collaboration embedding Claude across ICON's Orbis platform; four production capabilities (site intelligence / study planning, enrolment-risk prediction, protocol optimisation, client-system integration); role-based rollout (Claude Code, Claude, Claude Science)
Royalty: None; a services / technology collaboration, financial terms undisclosed, no stream
Context: Anthropic frames enrolment, a bottleneck that delays up to 80% of trials, as the target problem; a workflow layer above the royalty universe. (In-house disclosure: Anthropic develops the model used to assist this newsletter's production.)
Date: Announced Tue July 28, 2026

Regulatory and Clinical Read-Through

AstraZeneca / Sonesitatug Vedotin: First Phase 3 Overall-Survival Win for an Anti-CLDN18.2 ADC in Gastric Cancer, on an Asset AstraZeneca Calls Wholly Owned but Which Carries a Keymed Royalty (Mon July 27)

AstraZeneca (LSE / Nasdaq: AZN) reported that sonesitatug vedotin (Sone-Ve; AZD0901 / CMG901), its CLDN18.2-targeted antibody-drug conjugate, met a key endpoint in the global Phase 3 CLARITY-Gastric01 trial, with a statistically significant and clinically meaningful improvement in overall survival in second- and later-line CLDN18.2-positive advanced gastric and gastroesophageal junction cancers versus investigator's choice (AstraZeneca release).

Sponsor / licensee: AstraZeneca (LSE / Nasdaq: AZN)
Originator / licensor: Keymed Biosciences and subsidiary KYM Biosciences (joint venture with Lepu Biopharma); exclusive global licence to AstraZeneca, 2023
Asset: sonesitatug vedotin (Sone-Ve; AZD0901 / CMG901), CLDN18.2-targeted MMAE antibody-drug conjugate; advanced gastric, GEJ, and esophageal adenocarcinoma
Readout: CLARITY-Gastric01 Phase 3, statistically significant and clinically meaningful OS improvement in 2L+ CLDN18.2-positive disease versus investigator's choice; first anti-CLDN18.2 ADC to show an OS benefit in the setting; 175 centres, 19 countries; companion diagnostic Ventana SP455
Royalty: Tiered royalty plus milestone ladder to Keymed / KYM Biosciences (Lepu JV); CLARITY-Gastric 02 initiation triggered a $45M milestone in March 2026; the OS win de-risks the royalty and remaining milestones
Context: AstraZeneca calls it the first pivotal readout from its wholly owned ADC portfolio, but CMG901 is licensed from Keymed / KYM (Lepu JV); the March 2026 CLARITY-Gastric 02 start alone triggered a $45M milestone, and the win could expand the addressable population to the roughly 60% of patients above the CLDN18.2 threshold.
Date: Announced Mon July 27, 2026

InnoCare / Fadeucravacitinib (ICP-488): Registrational Phase 3 in Plaque Psoriasis Meets Primary Endpoint on an Internally Owned Oral TYK2 Inhibitor (Mon July 27)

InnoCare Pharma (HKEX: 09969; SSE: 688428) announced that its oral allosteric TYK2 inhibitor fadeucravacitinib (ICP-488) met the primary endpoint, with statistical significance and clinically meaningful improvement, in a registrational Phase 3 study in moderate-to-severe plaque psoriasis, along with multiple secondary endpoints (InnoCare release).

Company: InnoCare Pharma (HKEX: 09969; SSE: 688428; Beijing; CEO Jasmine Cui)
Asset: fadeucravacitinib (ICP-488), oral selective allosteric TYK2 inhibitor; moderate-to-severe plaque psoriasis
Readout: Registrational Phase 3 primary endpoint met with statistical significance and clinical meaningfulness; multiple secondary endpoints met; numerical data to be presented at a future congress; second Phase 3 study ongoing
Royalty: None; internally discovered and owned; positive re-rate, no stream travels
Date: Announced Mon July 27, 2026

AstraZeneca / Ultomiris (Ravulizumab): Adult and Adolescent HSCT-TMA Phase 3 Misses Primary Endpoint; Paediatric Arm Positive, Internally Owned (Mon July 27)

AstraZeneca (LSE / Nasdaq: AZN), through its Alexion rare-disease unit, reported that Ultomiris (ravulizumab) did not achieve statistical significance for the primary endpoint of event-free survival through 26 weeks versus placebo in the ALXN1210-TMA-313 Phase 3 trial in adults and adolescents aged 12 and older with thrombotic microangiopathy after haematopoietic stem cell transplant (AstraZeneca release).

Owner: AstraZeneca / Alexion (LSE / Nasdaq: AZN)
Asset: Ultomiris (ravulizumab), long-acting C5 complement inhibitor; HSCT-TMA
Readout: ALXN1210-TMA-313 (adults and adolescents 12+) missed the primary endpoint of event-free survival through 26 weeks; trend not significant; 146 patients, 18 countries. Paediatric ALXN1210-TMA-314 positive (OS 87.2% at 26 weeks, 73.4% at 52 weeks); paediatric filings advancing
Royalty: None of note; internally owned Alexion asset
Date: Announced Mon July 27, 2026

MapLight Therapeutics / ML-007C-MA: Phase 2 ZEPHYR Hits in Schizophrenia on a Muscarinic Combination, an Internally Owned Re-Rate (Mon July 27)

MapLight Therapeutics (Nasdaq: MPLT) reported that the registration-designed Phase 2 ZEPHYR study of ML-007C-MA, an oral fixed-dose combination of the M1/M4 muscarinic agonist ML-007 (betovumeline) and the peripherally acting anticholinergic fesoterodine, met its primary endpoint in schizophrenia (MapLight release).

Company: MapLight Therapeutics (Nasdaq: MPLT)
Asset: ML-007C-MA, oral fixed-dose M1/M4 muscarinic agonist ML-007 (betovumeline) plus peripherally acting anticholinergic fesoterodine; schizophrenia
Readout: Phase 2 ZEPHYR met the primary endpoint (210/3 mg BID; PANSS total, Week 5; ES 0.37, p equals 0.015; completer ES 0.50, p equals 0.002); the 330/6 mg QD arm missed
Royalty: None disclosed; internally owned; positive re-rate, no stream travels
Source: MapLight IR release (27 Jul)
Context: A positive clinical re-rate on a recent-IPO CNS name; the once-daily 330/6 mg arm missed while the twice-daily 210/3 mg dose hit.
Date: Announced Mon July 27, 2026

GSK / Hansoh Pharma (ris-rez): A Second Phase 3 Win for the B7-H3 ADC, This Time in Relapsed Osteosarcoma, Re-Rating the Hansoh Royalty (Tue July 28)

GSK (LSE / NYSE: GSK) and licensor Hansoh Pharma (HKEX: 03692) reported that a China Phase 3 trial of risvutatug rezetecan (ris-rez; HS-20093), their B7-H3-targeted topoisomerase-inhibitor ADC, met its primary endpoint in relapsed osteosarcoma, with significantly longer progression-free survival than chemotherapy (GSK release; Fierce Biotech).

Sponsor / licensee: GSK (LSE / NYSE: GSK; ex-Greater-China rights)
Originator / licensor: Hansoh Pharma (HKEX: 03692; retains Greater China)
Asset: risvutatug rezetecan (ris-rez; HS-20093 / GSK5764227), B7-H3-targeted topoisomerase-inhibitor ADC
Readout: China Phase 3 in relapsed osteosarcoma (at least two prior lines) met the primary endpoint of PFS versus chemotherapy; consistent secondary benefit including OS; no new safety signals; China submission planned; second Phase 3 win after the July 10 SCLC OS readout
Royalty: Hansoh tiered royalty on GSK ex-China net sales plus milestone ladder (December 2023 licence: $185M upfront, up to $1.525B milestones, about $1.7B deal value); the win widens the indication base and de-risks the ladder
Context: The second ris-rez Phase 3 win in three weeks (after the July 10 SCLC overall-survival readout); GSK carries but does not own the asset (December 2023 Hansoh licence, $185M up, up to $1.525B, tiered royalties), and the competitive marker is Daiichi Sankyo / Merck's I-DXd.
Date: Announced Tue July 28, 2026

Atea Pharmaceuticals (BEM/RZR): C-BEYOND Phase 3 Hits in HCV, the First Head-to-Head Phase 3 Win Versus Epclusa, on a Combo Carrying a Merck Royalty (Tue July 28)

Atea Pharmaceuticals (Nasdaq: AVIR) reported positive topline results from C-BEYOND, its North American pivotal Phase 3 trial of the once-daily fixed-dose combination of bemnifosbuvir and ruzasvir (BEM/RZR) for chronic hepatitis C (Atea release).

Company: Atea Pharmaceuticals (Nasdaq: AVIR; Boston)
Asset: BEM/RZR, once-daily fixed-dose bemnifosbuvir (nucleotide polymerase inhibitor, Atea-owned) plus ruzasvir (NS5A inhibitor, in-licensed from Merck); chronic HCV
Readout: C-BEYOND (North America) met the primary endpoint of non-inferiority versus SOF/VEL (Epclusa); first successful head-to-head Phase 3 in HCV; eight-week regimen for non-cirrhotic patients; SVR12, mITT, about 880 patients; C-FORWARD (ex-NA) reads out year-end 2026
Royalty: Upstream Merck royalty and milestones on ruzasvir (the NS5A component); the win de-risks that stream; rate undisclosed
Context: Framed as the first successful head-to-head Phase 3 in HCV, an eight-week regimen versus twelve for SOF/VEL (Epclusa) across about 880 patients; the win de-risks the upstream Merck royalty on ruzasvir.
Date: Announced Tue July 28, 2026

AstraZeneca H1 2026: Core EPS Ahead of Consensus, the $80B-by-2030 Target Reaffirmed, With the Royalty Reads in the Growth Drivers (Mon July 27)

AstraZeneca (LSE / Nasdaq: AZN) reported H1 2026 total revenue of about $30,672M (up 9% actual, 6% at constant exchange rates) and Q2 core EPS of $2.63, ahead of consensus, and reaffirmed full-year guidance and the $80B-by-2030 revenue target (AstraZeneca H1 & Q2 2026 results).

Company: AstraZeneca (LSE / Nasdaq: AZN)
Print: H1 2026 revenue about $30,672M (up 9% actual, 6% CER); Q2 core EPS $2.63, ahead of consensus; FY guidance and the $80B-by-2030 target reaffirmed
Royalty reads: sonesitatug vedotin (Keymed / KYM royalty, re-rated same day); Enhertu (Daiichi Sankyo profit-share and royalty); Imfinzi plus enfortumab vedotin (Astellas and Pfizer-Seagen royalty on EV)
Source: AstraZeneca H1 & Q2 2026 results (27 Jul)
Context: Royalty reads sit in the growth drivers: sonesitatug (Keymed / KYM), Enhertu (Daiichi Sankyo profit-share and royalty), and Imfinzi plus EV (Astellas and Pfizer-Seagen royalty on enfortumab vedotin).
Date: Reported Mon July 27, 2026

GSK Q2 2026: Guidance Held, Camlipixant Written Off, Nuvalent Assets Folded In (Tue July 28)

GSK (LSE / NYSE: GSK) reported Q2 2026 before the US open, reaffirming full-year guidance and its 2031 outlook of more than £40B in sales (GSK Q2 2026 results).

Company: GSK (LSE / NYSE: GSK)
Print: Q2 2026 reported pre-market 28 Jul; FY guidance and the 2031 more-than-£40B outlook reaffirmed
Royalty and pipeline reads: royalty income down 17% to £204M; camlipixant (ex-BELLUS 2023, roughly $2.0B) discontinued 11 Jul with a £1,334M impairment (CALM-1/CALM-2 stopped); rhinovirus asset GSK3923868 deleted; Nuvalent assets (£8.0B / about $10.6B, closed 15 Jul) fold in zidesamtinib (Jideytro) and neladalkib (PDUFA 27 Nov 2026); 2026 Phase 3 starts raised to more than 20
Source: GSK Q2 2026 results (28 Jul)
Context: The £1,334M camlipixant impairment (ex-BELLUS) is part of £1,895M total for the quarter, offset by the £8.0B / about $10.6B Nuvalent assets (zidesamtinib, whose approval was covered in W30, and neladalkib); the early-stage rhinovirus candidate GSK3923868 was deleted.
Date: Reported Tue July 28, 2026

Federal Circuit / Boston Scientific v. University of Texas: A Marketed-Product University Royalty on Drug-Eluting Stents Extinguished on Appeal (Mon July 27)

In a precedential opinion, the US Court of Appeals for the Federal Circuit reversed a Delaware jury verdict that had found Boston Scientific's (NYSE: BSX) drug-eluting coronary stent systems infringed a University of Texas System patent (US 6,596,296), granting Boston Scientific judgment as a matter of law on both invalidity and non-infringement and cancelling the royalties owed to the university (Law360, 27 Jul).

Parties: Boston Scientific (NYSE: BSX; appellant) and the Board of Regents of the University of Texas System (royalty holder)
Ruling: Federal Circuit reversal (precedential); JMOL of invalidity (anticipation over the 1994 "Song" reference) and non-infringement on US 6,596,296; drug-eluting coronary stent systems
Royalty: University of Texas royalty on Boston Scientific stent sales extinguished; prior award about $42M plus $7.4M interest cancelled; costs to the university
Context: A reminder that a litigated, single-patent university royalty on a long-marketed product carries reversal risk a diversified, licence-based stream does not, the fragility that argues for portfolio structure over single-asset litigation claims.
Date: Decided Mon July 27, 2026

Roche / Genentech v. Biocon: A Fresh Patent Suit Over the Proposed Perjeta (Pertuzumab) Biosimilar, a Branded-Franchise Base Defence Rather Than a Stream Event (Thu July 30)

Roche and its Genentech unit sued Biocon in the US District Court for the District of New Jersey over its proposed biosimilar of the breast-cancer antibody Perjeta (pertuzumab), candidate BMAB 1500 / PERT-IJS

Parties: Roche and Genentech (plaintiffs) v. Biocon (Biocon Biologics; defendant)
Product at issue: Perjeta (pertuzumab), HER2-directed antibody for HER2-positive breast cancer; Biocon's proposed biosimilar BMAB 1500 / PERT-IJS; US Perjeta sales about $1.70B ($1,702M, 2025)
Action: New patent-infringement suit over the proposed biosimilar; follows Genentech's February 27, 2026 ITC Section 337 complaint against the same candidate, whose current status is unconfirmed and to be checked against the ITC docket; parallels the settled Henlius / Organon Poherdy BPCIA case; Biocon FDA approval possible by end-2026
Royalty: No stream extinguished or created; a branded-franchise base-defence read-through (biosimilar timing as the driver of large-molecule royalty-base erosion); no CFC-relevant royalty disclosed on Perjeta
Date: Reported Thu July 30, 2026

Altimmune / Pemvidutide: RECLAIM Phase 2 Hits in Alcohol Use Disorder, an Internally Owned Re-Rate (Tue July 28)

Altimmune (Nasdaq: ALT) reported positive topline results from the RECLAIM Phase 2 trial of pemvidutide, its balanced glucagon and GLP-1 dual receptor agonist, in alcohol use disorder (Altimmune release).

Company: Altimmune (Nasdaq: ALT)
Asset: pemvidutide, balanced glucagon and GLP-1 dual receptor agonist; alcohol use disorder (and MASH, obesity)
Readout: RECLAIM Phase 2 met the primary endpoint (heavy drinking days minus 4.20 per week vs minus 2.75 placebo; difference 1.45 days, p equals 0.0014); about 9.1% placebo-adjusted weight loss; registrational secondary endpoints met
Royalty: None; internally owned; positive re-rate, no stream travels
Context: About 100 patients; heavy drinking days cut by 4.20 per week versus 2.75 on placebo (p=0.0014), with about 9.1% placebo-adjusted weight loss; the PERFORMA Phase 3 in MASH is planned for Q3 2026.
Date: Announced Tue July 28, 2026

Replimune / RP1: A Two-Day Round Trip, Briefing-Document Setback Reversed by a 10-3 Advisory-Committee Win in Melanoma (Tue July 28 to Thu July 30)

Replimune (Nasdaq: REPL) swung hard across two days. Shares first fell about 31% on July 28 after FDA staff briefing documents described the single-arm Phase 1/2 IGNYTE data package for RP1 (vusolimogene oderparepvec) plus nivolumab in advanced melanoma as not interpretable, then rebounded sharply after hours on July 30 when the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) voted 10 to 3 that the IGNYTE efficacy results are evaluable and clinically meaningful (briefing coverage; adcomm outcome).

Company: Replimune (Nasdaq: REPL; Woburn, MA; CEO Sushil Patel)
Asset: RP1 (vusolimogene oderparepvec), HSV-1-based oncolytic immunotherapy, plus nivolumab (BMS); advanced melanoma, anti-PD-1-pretreated
Event: July 28 briefing documents called the single-arm IGNYTE package not interpretable (FDA re-analysis: ORR 15.7% vs 33.6% claimed; DOR 14.1 vs 24.8 months), shares down about 31%; July 30 CTGTAC voted 10-3 that the efficacy is evaluable and clinically meaningful, shares up sharply after hours; PDUFA August 2
Royalty: None travels; RP1 proprietary to Replimune, nivolumab BMS
Context: FDA staff had cut the sponsor's 33.6% ORR to 15.7% and 24.8-month duration to 14.1 months, the third setback after two prior complete response letters, before the committee sided with the sponsor 10 to 3.
Date: Briefing documents Tue July 28, 2026; favorable adcomm Thu July 30, 2026 (PDUFA August 2)

J&J / RYBREVANT FASPRO (Subcutaneous Amivantamab): FDA Priority Review in Head and Neck Cancer Widens the Base on a Genmab and Halozyme Royalty Stack (Thu July 30)

Johnson & Johnson (NYSE: JNJ) announced that the FDA granted Priority Review to the supplemental BLA for RYBREVANT FASPRO (subcutaneous amivantamab plus hyaluronidase-lpuj) in adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who have progressed after platinum chemotherapy and a PD-1 or PD-L1 inhibitor (J&J release).

Sponsor: Johnson & Johnson (NYSE: JNJ)
Asset: RYBREVANT FASPRO (subcutaneous amivantamab plus hyaluronidase-lpuj), EGFR x MET bispecific antibody co-formulated with Halozyme ENHANZE; 2L+ recurrent or metastatic HNSCC (HPV-unrelated)
Event: FDA Priority Review granted to the sBLA (about six-month review); supported by Phase 1b/2 OrigAMI-4 (42% ORR monotherapy, >1/3 complete responses); would be first EGFR/MET-targeted therapy in the setting
Royalty stack: Genmab 8-10% DuoBody royalty on worldwide RYBREVANT net sales (reduced for the Genmab share of J&J's Halozyme royalty and where no patents exist), with a Genmab sub-royalty to Medarex; plus a Halozyme ENHANZE royalty on the SC co-formulation (ENHANZE platform covered in W30 via the Incyte licence); the indication expansion widens the base on both
Context: OrigAMI-4 showed a 42% ORR with over a third complete responses; if approved it would be the first EGFR- and MET-targeted therapy in this setting (about 15% five-year survival), widening the base on an already 40-plus-country franchise.
Date: Announced Thu July 30, 2026

Pfizer / LITFULO (Ritlecitinib): Two Phase 3 Wins in Nonsegmental Vitiligo on an Internally Owned Oral JAK3/TEC Inhibitor, No Stream (Thu July 30)

Pfizer (NYSE: PFE) reported positive topline results from two pivotal Phase 3 trials, TRANQUILLO and TRANQUILLO 2, of LITFULO (ritlecitinib) in nonsegmental vitiligo (NSV), both meeting their co-primary endpoints with significant improvements in facial and total-body repigmentation (F-VASI and T-VASI) versus placebo at Week 52 (Pfizer release).

Company: Pfizer (NYSE: PFE)
Asset: LITFULO (ritlecitinib), oral JAK3 and TEC-family kinase inhibitor; nonsegmental vitiligo (label expansion; already approved in severe alopecia areata)
Readout: TRANQUILLO and TRANQUILLO 2 both met co-primary endpoints (facial and total-body repigmentation vs placebo at Week 52); largest oral-systemic NSV Phase 3 program; global filings planned
Royalty: None; internally discovered and owned by Pfizer; positive re-rate, no stream
Context: The largest Phase 3 program to date for an oral systemic NSV therapy (TRANQUILLO in ages 12+, TRANQUILLO 2 in adults); LITFULO is already approved in severe alopecia areata, so this is a label-expansion re-rate.
Date: Announced Thu July 30, 2026

Karyopharm / Selinexor (XPOVIO): Phase 3 Endometrial-Cancer Miss With a PFS Trend, Capping the Royalty-Base Expansion on an Ex-US Licensee Network (Thu July 30)

Karyopharm Therapeutics (Nasdaq: KPTI) reported topline results from the Phase 3 XPORT-EC-042 trial of selinexor as maintenance-only therapy versus placebo in TP53 wild-type advanced or recurrent endometrial cancer; the trial missed its primary endpoint, though a trend favoured selinexor with a 5.3-month improvement in median PFS in the mITT population (Karyopharm release).

Company: Karyopharm Therapeutics (Nasdaq: KPTI; Newton, MA)
Asset: selinexor (XPOVIO / NEXPOVIO), first-in-class oral XPO1 inhibitor; TP53 wild-type advanced or recurrent endometrial cancer (maintenance)
Readout: XPORT-EC-042 Phase 3 missed the primary endpoint; 5.3-month median-PFS trend favouring selinexor (mITT); no new safety signals; Karyopharm cutting endometrial investment, prioritising myelofibrosis and multiple myeloma; shares up about 2.19% on the day
Royalty: Karyopharm is the originator-licensor and receives tiered ex-US royalties from Antengene, Menarini, Neopharm, and FORUS (Q1 2026 royalty revenue $1.9M); the miss caps indication-driven royalty-base expansion but extinguishes no existing stream
Context: The small-cap mirror of the RYBREVANT read: selinexor is marketed ex-US as XPOVIO / NEXPOVIO via Antengene, Menarini, Neopharm, and FORUS across 50-plus territories (royalty revenue $1.9M in Q1 2026), and the miss caps that base's growth without extinguishing existing royalties.
Date: Announced Thu July 30, 2026

Corbus / CRB-701 (SYS6002): FDA Clears a Registrational Head-and-Neck Trial on a China-In-Licensed Nectin-4 ADC, Re-Rating a CSPC Royalty (Tue July 28)

Corbus Pharmaceuticals (Nasdaq: CRBP) said the FDA cleared its registrational TEMPO-1 study of CRB-701 (SYS6002), a Nectin-4-targeted antibody-drug conjugate, in second-line oropharyngeal squamous cell carcinoma (Corbus release).

Sponsor / licensee: Corbus Pharmaceuticals (Nasdaq: CRBP)
Originator / licensor: CSPC Megalith Biopharmaceutical (China; upstream milestone and royalty holder)
Asset: CRB-701 (SYS6002), Nectin-4-targeted ADC; 2L oropharyngeal squamous cell carcinoma
Event: FDA cleared the registrational TEMPO-1 study (about 250 patients; enrolment from September 2026); ASCO 2026 data (ORR 42.9%, median DoR 6.3 months, median PFS 5.6 months at 3.6 mg/kg)
Royalty: Upstream CSPC Megalith milestone and royalty stack; the clearance advances the China-origin royalty toward a registrational base
Context: ASCO 2026 data showed a confirmed 42.9% ORR and 6.3-month median duration of response at 3.6 mg/kg; the roughly 250-patient registrational trial enrols from September 2026, re-rating the upstream CSPC Megalith royalty.
Date: Announced Tue July 28, 2026

Sanofi Q2 2026: A €1,031M Impairment and Three Immunology Discontinuations, With Amlitelimab the Largest Write-Off (Thu July 30)

Sanofi (Nasdaq / Euronext: SNY) reported Q2 2026 and booked an impairment expense of €1,031M, mainly €952M tied to the amlitelimab intangible, alongside the discontinuation of three immunology assets: amlitelimab, itepekimab, and balinatunfib (Sanofi Q2 2026 results).

Company: Sanofi (Nasdaq / Euronext: SNY)
Print: Q2 2026; €1,031M impairment (mainly €952M amlitelimab); discontinued amlitelimab, itepekimab, and balinatunfib
Royalty reads: amlitelimab is an ex-Kymab internal asset (no third-party royalty); itepekimab is a Sanofi-Regeneron asset; same-day Takeda / Regeneron / BMS pipeline cuts may de-rate specific upstream milestone or royalty holders; Alnylam's same-day guidance cut is the sharper royalty-base read
Source: Sanofi Q2 2026 results (30 Jul)
Context: Amlitelimab is ex-Kymab (2021), so the write-off is an internalised-asset impairment, not a third-party royalty event; the cleaner royalty read is Alnylam's same-day guidance cut (product revenue trimmed to $5.275B to $5.725B), amid coordinated pruning at Takeda (TAK-101), Regeneron, and BMS (BMS-986365).
Date: Reported Thu July 30, 2026

Keros / Takeda (Elritercept): First Dosing in the Phase 3 ELRiSE MDS Trial Crystallises a $20M Milestone on a $1.1B-Plus Royalty-Bearing Licence (Thu July 30)

Keros Therapeutics (Nasdaq: KROS) said it will receive a $20M development milestone from Takeda following dosing of the first patient in the Phase 3 ELRiSE trial of elritercept (KER-050) in myelodysplastic syndromes (Keros release).

Originator / licensor: Keros Therapeutics (Nasdaq: KROS; Lexington, MA; TGF-beta biology)
Licensee: Takeda (global ex-mainland-China / Hong Kong / Macau; funds and commercialises)
Asset: elritercept (KER-050), ActRIIA-Fc ligand trap; transfusion-dependent anaemia in lower-risk MDS (Phase 3 ELRiSE and RENEW)
Event: First-patient dosing in Phase 3 ELRiSE triggers a $20M development milestone (distinct from the $10M RENEW first-dosing milestone in July 2025)
Royalty: Under the January 2025 licence ($200M upfront, more than $1.1B potential milestones, tiered royalties on net sales); the dosing advances the ladder
Context: A pay-as-you-go originator position: a separate RENEW first-dosing milestone already triggered $10M in July 2025, and Keros returns part of net milestone cash to shareholders.
Date: Announced Thu July 30, 2026

Funds and Capital

Micron Biomedical / NIAID: $4.5M Contract for a Dissolvable-Microarray Radiation Countermeasure Built on an In-Licensed TLR5 Agonist (Mon July 27)

Micron Biomedical (private) was awarded a $4.5M contract by the US National Institute of Allergy and Infectious Diseases (NIAID) to develop a dissolvable-microarray medical countermeasure against acute radiation syndrome (Micron release).

Funder: US National Institute of Allergy and Infectious Diseases (NIAID) ($4.5M contract; non-dilutive)
Recipient: Micron Biomedical (private; dissolvable-microarray delivery)
Asset: xempritolimod, TLR5 agonist in-licensed from Connext; acute radiation syndrome (ARS); efficacy shown in murine and NHP irradiation models
Royalty: No government royalty; upstream Connext economic interest via the in-licence
Source: Micron Biomedical release (27 Jul)
Context: xempritolimod (in-licensed from Connext) has shown efficacy in murine and nonhuman-primate irradiation models; non-dilutive funding above an upstream Connext interest.
Date: Announced Mon July 27, 2026

Apnimed: IPO Priced at the Top of the Range and Upsized 20%, Debuting on an Oral Obstructive-Sleep-Apnea Pill (Launched Mon July 27, Priced Thu July 30, Trading Fri July 31)

Apnimed (Nasdaq: APMD) priced its IPO on the evening of July 30, upsizing the deal 20% to 12M shares (from 10M) and pricing at $16.00, the top of the $14 to $16 range, for gross proceeds of about $192M, with trading to open on the Nasdaq Global Select Market on July 31 (Apnimed pricing release). Proceeds fund AD109 (Oxnimbi), an oral fixed-dose anti-apneic neuromuscular modulator (a novel anti-muscarinic plus a selective norepinephrine reuptake inhibitor) for obstructive sleep apnea, evaluated in about 1,300 patients across Phase 3 trials.

Issuer: Apnimed (Nasdaq: APMD; Cambridge, MA)
Asset: AD109 (Oxnimbi), oral fixed-dose anti-muscarinic plus NRI neuromuscular modulator for obstructive sleep apnea; about 1,300 patients across Phase 3 trials; would be the first oral OSA therapy if approved
Terms: Priced 30 Jul; upsized to 12M shares (from 10M) at $16.00, top of the $14 to $16 range; gross proceeds about $192M (before the underwriters' option); BofA Securities, Evercore ISI, Cantor, LifeSci Capital; trading 31 Jul; close on or about August 3
Royalty: None disclosed
Source: Apnimed pricing release (30 Jul)
Context: The first biotech IPO to price and debut inside W31 (after W30's Scribe); reportedly multiple times oversubscribed, book-run by BofA, Evercore ISI, Cantor, and LifeSci Capital; shares opened at $22.00 on the July 31 debut, well above the $16.00 IPO price; AD109 would be the first oral pill for OSA if approved. Apnimed last featured in W15 on its $150M HealthCare Royalty (HCRx) facility carrying a synthetic royalty on AD109 net sales.
Date: Launched Mon July 27, priced Thu July 30, trading Fri July 31, 2026

Vogenx: IPO on File for an SGLT1 Inhibitor Carrying a Kissei High-Single-Digit Royalty (Terms Set, Not Yet Priced)

Vogenx (proposed Nasdaq: VOGX; Research Triangle Park, NC) is on file for a Nasdaq IPO to fund mizagliflozin, an oral SGLT1 inhibitor, with a proposed raise of about $75M (roughly 6.25M shares at $11 to $13) that had set a range but not priced by the W31 cut-off (Vogenx S-1).

Issuer: Vogenx, Inc. (proposed Nasdaq: VOGX; Research Triangle Park, NC)
Asset: mizagliflozin, oral SGLT1 inhibitor; post-bariatric hypoglycaemia (Phase 2 done), gastroparesis, glucose-dependent syndrome
Terms (on file): about $75M proposed (roughly 6.25M shares at $11 to $13, plus overallotment); range set, not yet priced; JonesTrading sole bookrunner
Royalty: Upstream Kissei Pharmaceutical (Japan) December 2021 licence, ex-Japan/Korea/Taiwan; about $27M future milestones plus a high-single-digit royalty on net sales (subject to reduction)
Context: Mizagliflozin was discovered by Japan's Kissei; lead indication is post-bariatric hypoglycaemia (Phase 2 complete), with gastroparesis to follow, a Japan-origin royalty beneath a US listing candidate.
Date: On file at the W31 cut-off (not priced in-window)

Xeltis: €20.5M Top-Up for the aXess US Pivotal and FDA Path, in a Medtech That Holds a Grand Pharma Greater China Royalty (Tue July 28)

Xeltis (private; Eindhoven, Netherlands and USA) raised an additional €20.5M from new and existing shareholders to advance aXess, its restorative vascular access conduit for hemodialysis, toward FDA approval and a US commercial launch (Xeltis release).

Company: Xeltis (private; Eindhoven, Netherlands and USA; CEO Eliane Schutte)
Raise: Additional €20.5M from new and existing shareholders; new investor Horizon 3 Healthcare led; European Innovation Council, Invest-NL, VI Partners, EQT Life Sciences, DaVita and others participating; builds on about €50M secured in 2025
Asset: aXess, restorative vascular access conduit for hemodialysis (end-stage renal disease); Restorex supramolecular-polymer platform; CE mark April 2026; first EU commercial implant July 2026; US pivotal NCT06494631 (past 50% enrolled), heading to FDA PMA; pipeline XABG (coronary) and XPAD (peripheral)
Royalty: No new stream from the raise; Xeltis holds a Greater China royalty via the Grand Pharma exclusive licence (August 2022 commitment of €15M blended equity and licence fees, completed with the February 2023 Series D2) for aXess and platform hemodialysis products, plus a Greater China pre-emptive negotiation right on other indications; standalone upfront, milestones, and rate undisclosed. Platform IP originated at TU Eindhoven and was internalised via the QTIS merger, so no running upstream royalty identified. DaVita is strategic equity only
Source: Xeltis release (28 Jul)
Context: Builds on roughly €50M secured in 2025; aXess holds a CE mark (April 2026) with a first commercial implant in Germany in July 2026, and the sole stream is Xeltis's Greater China entitlement from Grand Pharma's August 2022 cornerstone (€15M blended).
Date: Announced Tue July 28, 2026

Claris Biotherapeutics: $118M Series B for the LSCD Eye Drop CSB-001, Sitting on a Kringle Pharma Ophthalmic Licence (Tue July 28)

Claris Biotherapeutics (private; Jersey City, NJ) closed a $118M Series B to advance CSB-001 (oremepermin alfa ophthalmic solution), a recombinant human deleted hepatocyte growth factor eye drop, toward a pivotal program in limbal stem cell deficiency (LSCD) (Claris release).

Company: Claris Biotherapeutics, Inc. (private; Jersey City, NJ; CEO Stephen Brady; Chairman Marc de Garidel)
Raise: $118M Series B, co-led by Samsara Biocapital and Catalio Capital Management; Adage Capital Management, Sofinnova Investments, Aisling Capital, ADAR1 Capital Management; existing holders Novo Holdings, Janus Henderson Investors, Mass General Brigham Ventures
Asset: CSB-001 (oremepermin alfa), recombinant human deleted HGF ophthalmic solution; limbal stem cell deficiency (LSCD); pivotal program 1H 2027; would be the first pharmacologic LSCD therapy
Royalty: Upstream exclusive worldwide ophthalmic licence to oremepermin alfa from Kringle Pharma (Japan), so a Kringle royalty and milestone entitlement rides above the asset; Harvard / Mass Eye and Ear academic origins; terms undisclosed
Context: If approved, CSB-001 would be the first pharmacologic therapy for LSCD; the science traces to the Harvard and Mass Eye and Ear labs of Reza Dana and Sunil Chauhan, with an upstream Kringle Pharma ophthalmic licence.
Date: Announced Tue July 28, 2026

CORE Biomedicine: A $21M Series A Plus an AMED Grant Capitalises the Newco That Sits Above Eisai's Retained Oncology Royalty (Tue July 28)

CORE Biomedicine (private; Boston, Tokyo, and Suzhou) closed a $21M Series A and, through its wholly owned CORE Biomedicine Japan subsidiary, secured a non-dilutive grant from Japan's AMED (the Strengthening Program for Pharmaceutical Startup Ecosystem) to advance its lineage-based precision-oncology pipeline (CORE release).

Company: CORE Biomedicine (private; Boston, Tokyo, Suzhou; CEO Dr. Ping Zhu; founded by ex-H3 Biomedicine leaders)
Raise: $21M Series A co-led by UTokyo Innovation Platform and Elikon Venture; InnoPinnacle Fund, Mitsubishi UFJ Capital, Suzhou Capital Group, CD Capital, YuanBio Venture Capital, Vision Incubate, Root Venture Partners; plus a non-dilutive AMED grant to CORE Biomedicine Japan
Assets: Lineage-based precision-oncology programs, including those in-licensed from Eisai (scored separately this issue); discovery through early clinical development
Royalty: No new stream from the round; capitalises the programme base on which Eisai retains milestones and royalties, so the financing sits above an upstream Eisai royalty; Japan and China syndicate
Context: Founded by former H3 Biomedicine (Eisai's US oncology unit) leaders, which links it to the same-day Eisai out-licence; UTokyo IPC seeded it in March 2025, and the syndicate is all-Japan-and-China.
Date: Announced Tue July 28, 2026

Lauxera Capital Partners / GenePlanet: Growth-Equity Investment Into a Central European Genomics Diagnostics Platform, With BlackPeak Partially Exiting, No Stream (Thu July 30)

Lauxera Capital Partners, a Paris- and San Francisco-based Healthtech investor, made a strategic growth-equity investment into GenePlanet, a Slovenia-rooted genomics and laboratory platform delivering genetic testing and next-generation-sequencing services, while BlackPeak Capital, GenePlanet's growth partner since 2023, partially exited and retained a stake (BlackPeak release).

Investor: Lauxera Capital Partners (Healthtech growth investor; Paris and San Francisco; Managing Partner Victor Decrion)
Company: GenePlanet (private; Central Europe; genomics / NGS diagnostics; Founder Marko Bitenc)
Seller: BlackPeak Capital (partial exit, retains a stake; Managing Partner Niklas Pichler)
Structure: Strategic growth-equity investment plus a partial secondary; funds international expansion, oncology and rare-disease panel development, and further bolt-ons; targets a full liquidity event for early investors within three to five years
Royalty: None; a diagnostics equity round and partial secondary; terms undisclosed, no stream
Context: GenePlanet grew from 24 to more than 50 markets under BlackPeak with four bolt-ons and pan-European labs (Zagreb, Sweden, Hungary); Lauxera is a Fund-of-the-Week candidate.
Date: Announced Thu July 30, 2026

Standard disclaimer

This Weekly Term Sheet is provided for informational purposes only. It does not constitute investment advice, an offer to sell or a solicitation of an offer to buy any security, or a recommendation regarding any investment. Data and disclosures are sourced from public company filings, press releases, and credible secondary reporting. Capital for Cures AG does not warrant the accuracy or completeness of information presented. Readers are advised to consult primary source documentation before making any investment, partnership, or commercial decision. Capital for Cures AG and its principals may hold positions in companies referenced.